146 related articles for article (PubMed ID: 9207464)
21. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia.
Perego RA; Costantini M; Cornacchini G; Gargantini L; Bianchi C; Pungolino E; Rovida E; Morra E
Eur J Cancer; 2000 Jul; 36(11):1395-401. PubMed ID: 10899653
[TBL] [Abstract][Full Text] [Related]
22. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Clark RE; Dodi IA; Hill SC; Lill JR; Aubert G; Macintyre AR; Rojas J; Bourdon A; Bonner PL; Wang L; Christmas SE; Travers PJ; Creaser CS; Rees RC; Madrigal JA
Blood; 2001 Nov; 98(10):2887-93. PubMed ID: 11698267
[TBL] [Abstract][Full Text] [Related]
23. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
[TBL] [Abstract][Full Text] [Related]
24. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells.
ten Bosch GJ; Toornvliet AC; Friede T; Melief CJ; Leeksma OC
Leukemia; 1995 Aug; 9(8):1344-8. PubMed ID: 7643623
[TBL] [Abstract][Full Text] [Related]
25. Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
Khazaal MS; Hamdan FB; Al-Mayah QS
Mol Genet Genomic Med; 2019 Aug; 7(8):e809. PubMed ID: 31206255
[TBL] [Abstract][Full Text] [Related]
26. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
[TBL] [Abstract][Full Text] [Related]
27. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
[TBL] [Abstract][Full Text] [Related]
28. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.
MacIntyre AR; Christmas SE; Clark RE
Exp Hematol; 1996 Sep; 24(11):1307-11. PubMed ID: 8862441
[TBL] [Abstract][Full Text] [Related]
29. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.
Pawelec G; Max H; Halder T; Bruserud O; Merl A; da Silva P; Kalbacher H
Blood; 1996 Sep; 88(6):2118-24. PubMed ID: 8822931
[TBL] [Abstract][Full Text] [Related]
30. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
31. Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
Winter SS; Greene JM; McConnell TS; Willman CL
Leukemia; 1999 Dec; 13(12):2007-11. PubMed ID: 10602422
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.
Clark RE; Christmas SE
Leuk Lymphoma; 2001; 42(5):871-80. PubMed ID: 11697642
[TBL] [Abstract][Full Text] [Related]
33. Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.
Abu-Eisha HM; Butt NM; Clark RE; Christmas SE
Leuk Res; 2007 Dec; 31(12):1675-81. PubMed ID: 17324459
[TBL] [Abstract][Full Text] [Related]
34. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
Makita M; Azuma T; Hamaguchi H; Niiya H; Kojima K; Fujita S; Tanimoto M; Harada M; Yasukawa M
Leukemia; 2002 Dec; 16(12):2400-7. PubMed ID: 12454745
[TBL] [Abstract][Full Text] [Related]
35. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.
Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA
Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568
[TBL] [Abstract][Full Text] [Related]
36. Proteosomal degradation of BCR/ABL protein can generate an HLA-A*0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated.
Posthuma EF; van Bergen CA; Kester MG; de Paus RA; van Veelen PA; de Ru AH; Drijfhout JW; Lurvink EG; Willemze R; Falkenburg JH
Haematologica; 2004 Sep; 89(9):1062-71. PubMed ID: 15377467
[TBL] [Abstract][Full Text] [Related]
37. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
[TBL] [Abstract][Full Text] [Related]
38. BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
Paramita DK; Hutajulu SH; Syifarahmah A; Sholika TA; Fatmawati S; Aning S; Sulistyawati D; Wahyuni S; Taroeno-Hariadi KW; Kurnianda J
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1545-1550. PubMed ID: 32592347
[TBL] [Abstract][Full Text] [Related]
39. T-cell immunity to the joining region of p210BCR-ABL protein.
Chen W; Peace DJ; Rovira DK; You SG; Cheever MA
Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1468-72. PubMed ID: 1346932
[TBL] [Abstract][Full Text] [Related]
40. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
